A rapid onset and short duration insulin secretogogue, mitiglinide, in combination with metformin versus metformin alone in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial for 6 months.

Trial Profile

A rapid onset and short duration insulin secretogogue, mitiglinide, in combination with metformin versus metformin alone in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial for 6 months.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2009

At a glance

  • Drugs Metformin; Mitiglinide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met, as reported in an Elixir Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top